To investigate if the clinically relevant melanoma therapy of combined BRAF and MEK inhibition sensitizes cancer cells for the treatment with the RIG-I ligand 3pRNA, we treated human A375 (BRAF V600E mutated), Ma-Mel-48 (H-Ras G13I), and murine YUMM1.7 (BRAF V637E is a homolog to human V600E, V637E is sensitive to dabrafenib24) melanoma cell lines with dabrafenib and trametinib, alone or in combination. This evidence concerns the gene MAP2K7 and cancer.